Pre-conference summary: NS5A Inhibitor—no data is available.
Pre-conference summary: Caspase Inhibitor—no data is available.
· LB-13. Non response to peginterferon alfa and ribavirin in IL28B CC & CT patients can be overcome by high dose continuous interferon alfa-2b administration in combination with ribavirin for chronic hepatitis C.
· 808. Virologic and Metabolic Responses in Chronic Hepatitis C (CHC) Genotype 1 (G1) Patients With Insulin Resistance (IR) Treated With Pioglitazone (PIO) and Peginterferon alfa-2a Plus Ribavirin (P/R) – Final Results of Week 12 Early Virologic Response.
Pre-conference summary: Thiazolides—Phase II study found that the combination of nitazoxanide plus pegylated interferon plus ribavirin to treat HCV genotype 1 treatment naïve patients increased the SVR rates to 44% compared to 32% in the group who received pegylated interferon plus ribavirin, did not receive nitazoxanide.
Pre-conference summary: The active ingredient in milk thistle that is believe to help improve liver health.
Pre-conference summary: Cyclophilin Inhibitor—Phase I studies have demonstrated a clinically relevant reduction in HCV RNA.
Pre-conference summary: Vitamin D has been shown to inhibit the replication of the hepatitis C virus and possibly increase the chances of treatment response.
Pre-conference summary: A therapeutic vaccine that is in phase II studies. In a Phase 2b study it was found that in people with HCV genotype 1 who were either treatment-naïve or prior non-responders and who received the triple combination of GI-5005, pegylated interferon and ribavirin that 74% achieved an end of treatment response.